{"id":"NCT02412111","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor","officialTitle":"A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That Is Clinically Demonstrated to be Ivacaftor Responsive","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06","primaryCompletion":"2017-09","completion":"2017-09","firstPosted":"2015-04-08","resultsPosted":"2019-01-08","lastUpdate":"2019-01-08"},"enrollment":156,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Ivacaftor","otherNames":["VX-770"]},{"type":"DRUG","name":"Tezacaftor/Ivacaftor","otherNames":["VX-661/VX-770"]}],"arms":[{"label":"Ivacaftor (Run-in Period)","type":"EXPERIMENTAL"},{"label":"VX-661 + Ivacaftor (Active comparator period)","type":"EXPERIMENTAL"},{"label":"Ivacaftor monotherapy (Active comparator period)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.","primaryOutcome":{"measure":"Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8","timeFrame":"Baseline, Through Week 8","effectByArm":[{"arm":"VX-661 + Ivacaftor (Active Comparator Period)","deltaMin":0.5,"sd":0.4},{"arm":"Ivacaftor Monotherapy (Active Comparator Period)","deltaMin":0.2,"sd":0.4}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.5846"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":68,"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Ireland","Italy","United Kingdom"]},"refs":{"pmids":["33339768"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":156},"commonTop":["Cough","Headache","Sputum increased","Infective pulmonary exacerbation of cystic fibrosis","Fatigue"]}}